Esophageal Cancer
Esophageal cancer treatment with gemcitabine/irinotecan exhibited considerable toxicity
Published in Clinical Oncology Week, June 5th, 2006
"Metastatic esophageal carcinoma is an incurable disease with median survival duration of 6 to 8 months. Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patients with advanced or metastatic esophageal carcinoma," researchers in the United States reported.
"Patient eligibility included a diagnosis of squamous cell or adenocarcinoma of the esophagus/gastroesophageal (GE) junction, metastatic or recurrent disease, no...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Appendiceal Carcinoids
Appendiceal carcinoids greater than 2.0 cm treated by simple appendectomy - Carcinogenesis
Breast cancer risk increased in A-T carriers from exposure to environmental carcinogens - Cervical Cancer
Cervical and corpus cancer survival striated according to socioeconomic status - Liver Cancer
Benefit of liver cancer screening in elderly reduced due to competing death risks - Radiotherapy
Nutritional support planning described for cancer patients undergoing radiotherapy - Anal Cancer
Elevated anal squamous cell carcinoma risk linked to benign inflammatory anal lesions - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
